Q-omics provides the consensus-scored NUDT9 profile across patient tissues and cancer cell-line models. NUDT9 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NUDT9 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, NUDT9 RNA expression shows 19,013 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUAD, and THYM as cancer lineages where NUDT9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUDT9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUDT9 survival associations across molecular data types. NUDT9 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUDT9 RNA expression–survival associations across cancer types. High NUDT9 expression shows unfavorable associations in UVM, LGG, STAD and HNSC, but favorable associations in KIRC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NUDT9 RNA expression.
This table summarizes NUDT9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NUDT9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUDT9 shows lower tumor expression in LUAD, THCA, COAD, KIRC and KIRP and higher tumor expression in LIHC. The LUAD box plot shows higher NUDT9 RNA expression in normal versus tumor tissue (log2 FC = −0.469, t-test p < 0.001).
This table shows molecular features associated with NUDT9 in patient tissues and cancer cell lines. In patient samples, NUDT9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUDT9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
